Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy
{{output}}
Introduction: Prostate cancer (PC), including castration-resistant disease (CRPC), remains largely driven by dysregulated androgen receptor (AR) signaling. While androgen deprivation therapy (ADT) combined with next-generation AR... ...
